Home

James A Schoeneck

CIK 1420987 · Interim President · last filed 2026-08-19

James A Schoeneck is an Interim President who has filed 76 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for CLDI, was dated Aug 19, 2026. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.5K across reported positions. 3 SEC filings were submitted jointly with ANAPTYSBIO, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.5K

Companies

6

Total Filings

76

Lifetime Open-Market Net

-$1.79M

Filer Profile

Reported Address
C/O DEPOMED, INC.
1360 O'BRIEN DRIVE
MENLO PARK, CA 94025
Related Filers
ANAPTYSBIO, INC — 3 joint filings, latest 2018-02-06
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CLDI Director 5,260 $1.24 $6.5K $150.0K 3 2026-08-19
KYNB Director — $7.97 — $0 1 2026-06-17
KYNTRA BIO, INC. (FGEN) Delisted Director 40,817 $9.75 $398.0K -$1.20M 28 2025-07-02
Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Director 2,035,668 $0.01 $11.8K $0 6 2024-10-15
ANAB Director — $53.87 — $0 2 2018-02-06
Assertio Therapeutics, Inc (DEPO) Delisted President and CEO 495,105 — — -$743.6K 35 2017-02-10

Recent Filings

76 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-19 CLDI Grant (A) — $0 EDGAR
2026-06-17 KYNB Grant (A) — $0 EDGAR
2025-08-25 CLDI Buy (P) +75,000 $150.0K EDGAR
2025-07-15 CLDI Grant (A) — $0 EDGAR
2025-07-02 KYNTRA BIO, INC. (FGEN) Delisted Buy (P) +23,567 $119.5K EDGAR
2025-06-06 KYNTRA BIO, INC. (FGEN) Delisted Grant (A) — $0 EDGAR
2025-03-24 KYNTRA BIO, INC. (FGEN) Delisted Buy (P) +300,000 $105.0K EDGAR
2024-10-15 Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Grant (A) — $0 EDGAR
2024-07-02 Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Grant (A) +79,687 $0 EDGAR
2024-07-02 Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Grant (A) +28,207 $0 EDGAR
Showing 1–10 of 76
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.